| Patient | Zora Neale Hurston |
|---|---|
| Date of birth | 1959-01-07 |
| Identifiers | MRN HR-ML040-SYN; SSN (made up) 000-40-6213 |
| Document date | 2026-06-01 |
| Author | Lorraine Abernathy-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Eight-week review: blood pressure, potassium, lipids and heart failure. [S]
Ms. Hurston returns eight weeks after spironolactone was added and two weeks after her sick visit for lightheadedness in the heat. She restarted chlorthalidone, spironolactone and dapagliflozin after two days, as planned; the lightheadedness has not returned since she moved her gardening to the early morning and drinks water through the day, and the energy assistance application for cooling help is in. She did not have the metabolic panel one to two weeks after starting spironolactone: the bus route to the laboratory changed, and she had no ride. Her home blood pressure average this week is 124/74, and she has no breathlessness on the stairs at school. Extra Help and the Medicare Savings Program were approved, and the SHINE counselor helped her choose a drug plan that begins next month. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 124/74 mmHg |
| Missed test | Metabolic panel one to two weeks after spironolactone not done; no ride to the laboratory |
| Since the sick visit | Medicines restarted after two days; no further lightheadedness |
| Coverage | Extra Help and Medicare Savings Program approved; drug plan begins next month |
| KCCQ-12 | 72, from 54 |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations or edema; breathless only on hurrying uphill |
| Neurological | Negative | No lightheadedness, headache, weakness or speech change |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Breast | Negative | No breast tenderness or swelling on spironolactone |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 2026-03-09 | active | S |
| Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) every morning | One-half tablet every morning | Oral route | 2026-03-09 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet daily; pause on days of vomiting, diarrhea or not eating or drinking | One tablet daily, with sick-day rules | Oral route | 2026-03-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily | One-half tablet daily | Oral route | 2026-04-06 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-01 | Body height | 165 | cm | S |
| 2026-06-01 | Body weight | 81.8 | kg | S |
| 2026-06-01 | Body mass index (BMI) [Ratio] | 30 | kg/m2 | S |
| 2026-06-01 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-06-01 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-06-01 | Heart rate | 72 | /min | S |
| 2026-06-01 | Respiratory rate | 16 | /min | S |
| 2026-06-01 | Body temperature | 36.6 | Cel | S |
| 2026-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-01 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 65 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-01 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-01 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-06-01 | Cholesterol [Mass/volume] in Serum or Plasma | 152 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-06-01 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 76 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-06-01 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 53 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-06-01 | Triglyceride [Mass/volume] in Serum or Plasma | 115 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-06-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 7-35 U/L | Normal | S |
| 2026-06-01 | Overall summary score [KCCQ-12] | 72 | {score} | S |
Vital signs recorded on 2026-06-01; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 126/76, pulse 72; weight 81.8 kg |
| Orthostatic vital signs | Standing at three minutes 122/74 mmHg without symptoms |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; S4 |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Very high blood pressure at intake (178/104 and 174/102 mmHg) with morning headaches for two months, without signs of a hypertensive emergency; not previously diagnosed; ambulatory monitoring to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting problem, resolved when ambulatory monitoring and the echocardiogram established the diagnosis at the second visit. Not a claim about her real blood pressure. |
| Breathlessness on exertion for three months (walking to the school, carrying groceries) with mild ankle swelling by evening; cause to be determined | resolved | confirmed | R06.09 | S — Synthetic presenting problem, resolved into the heart failure diagnosis at the second visit. |
| Hypertensive heart disease with heart failure: stage 2 hypertension confirmed by 24-hour ambulatory monitoring (mean 158/96 mmHg, non-dipping at night), with concentric left ventricular hypertrophy on ECG and echocardiogram; synthetic modern episode linked to the hypertensive heart disease recorded as her cause of death | active | confirmed | I11.0 | S — Synthetic modern diagnosis made at the second visit; the 1960 cause of death remains D. |
| Heart failure with preserved ejection fraction (ejection fraction 62%), NYHA class II, with grade II diastolic dysfunction and an enlarged left atrium | active | confirmed | I50.32 | S — Synthetic modern diagnosis confirmed by echocardiogram and cardiology at the second visit. |
| Food insecurity: food runs short at the end of most months (Hunger Vital Sign positive) | active | confirmed | Z59.41 | S — Synthetic social need anchored to her documented poverty. |
| Low and irregular income from substitute teaching and newspaper writing, with Original Medicare but no drug coverage; medicine costs a barrier | active | confirmed | Z59.6 | S — Synthetic social need anchored to her documented low income in the 1950s. |
| Orthostatic hypotension with lightheadedness on standing, from volume depletion in early summer heat on a diuretic, spironolactone and an SGLT2 inhibitor; no fall or faint; resolved after two days off those medicines and more fluid | resolved | confirmed | I95.1 | S — Synthetic intercurrent problem at an unscheduled visit; it follows from the treatment plan and the climate and does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic (seated, average of two readings, large cuff) | Every visit | Completed today | 126/76 mmHg; no orthostatic drop |
| Examination | Out-of-office blood pressure (ambulatory at diagnosis; home readings when treatment changes) | At diagnosis and with each treatment change | Completed today | Home average 124/74 mmHg |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 81.8 kg; jugular venous pressure not raised; no edema; NYHA I to II |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, SGLT2 inhibitor or MRA; then every three to six months | Deferred | The panel due one to two weeks after spironolactone was started was missed: the bus route to the laboratory changed and she had no ride. The first check came at the sick visit six weeks after the start: potassium 4.4 mmol/L, with creatinine 1.10 mg/dL from volume depletion in the heat, not from the potassium. No harm from the missed check is evident: no hyperkalemia at six weeks or today. Corrective action: laboratory tests on clinic visit days where possible, and rides through the county's transportation program for any separate trip |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, SGLT2 inhibitor or MRA; then every three to six months | Completed today | Sodium 138, potassium 4.2, creatinine 0.96 mg/dL (eGFR 65), magnesium 2.0 |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Completed today | Ten weeks on atorvastatin: LDL 76 mg/dL, total cholesterol 152, HDL 53, triglycerides 115; ALT 19 U/L |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Completed today | 72, from 54 at diagnosis |
| Imaging | ECG and echocardiogram | At diagnosis; repeat only with unexplained clinical change | Not indicated | Improving; no unexplained change |
| Medication safety | SGLT2 inhibitor and MRA: volume depletion, potassium and sick-day rules | Every visit | Completed today | Orthostatic episode in the heat managed by the sick-day rules; no recurrence; potassium in range |
| Self-management | Self-care: daily weights, less salt, sick-day rules and the BE FAST stroke signs | Every visit | Completed today | Daily weights; heat plan; BE FAST reviewed |
| Medication safety | Medicine costs and coverage (generics, 90-day fills, patient assistance, Extra Help, Medicare Savings Program) | Every visit | Completed today | Extra Help and Medicare Savings Program approved; drug plan begins next month |
| Self-management | Food access | Every visit | Completed today | Food lasts the month with SNAP and the pantry |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, hypertension and heart failure monographs (2026); Signs and Symptoms of Stroke (2026); Help with drug costs (Extra Help) (2026); Medicare Savings Programs (2026); Low Income Home Energy Assistance Program (LIHEAP) (2026)
Follow-up: Annual wellness visit in about three months. Heart failure and blood pressure review in about four months with a metabolic panel and the KCCQ-12. Call for lightheadedness or a weight change beyond the plan; call 911 for any BE FAST sign. Next scheduled visit 2026-09-14: subsequent annual wellness visit. [S]